iShares U.S. Pharmaceuticals ETF IHE
110.45 USD -0.64 (-0.57%)
Nov 12, 2026, 3:54 PM EST
110.44 Day range 110.64
79.82 52-week range 111.98
- YTD
- +30.20%
- 1 year
- +37.32%
News
fool.com Which Is the Better Buy: iShares' Pharma ETF IHE or First Trust's Biotech Fund FBT? iShares U.S. Pharmaceuticals ETF has a lower expense ratio than the First Trust NYSE Arca Biotechnology Index Fund. First Trust NYSE Arca Biotechnology Index Fund maintains a more concentrated…
zacks.com ETFs in Spotlight as FDA Vision Loss Warning Meets Lilly's Sleep Apnea Win Eli Lilly's sleep apnea breakthrough amid the FDA's vision-loss warning puts diversified healthcare ETFs in the spotlight.
zacks.com Pharmaceuticals ETF (IHE) Hits a New 52-Week High For investors seeking momentum, iShares U.S. Pharmaceuticals ETF IHE is probably on the radar. The fund just hit a 52-week high and is up 42.76% from its 52-week low price of $77.52/share.
fool.com Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors The iShares U.S. Pharmaceuticals ETF offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF. The iShares Biotechnology ETF provides exposure to a…
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
benzinga.com Two Years to Build or Pay 200% — Which US Pharma Stocks Win? Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
benzinga.com Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery Bristol Myers Squibb expands AI efforts through Anthropic and Tempus partnerships as shares edge higher Wednesday.
benzinga.com UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs UNH earnings reveal rising margin pressure from Medicare Advantage; investors may look to these healthcare ETFs for diversification.
benzinga.com Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
benzinga.com Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is cushioning ETFs despite pricing pressure.
benzinga.com Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
benzinga.com Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.
benzinga.com Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
benzinga.com Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
benzinga.com Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
benzinga.com Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
benzinga.com Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
benzinga.com Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken…
benzinga.com Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
benzinga.com Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
benzinga.com Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
benzinga.com Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
benzinga.com Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
benzinga.com Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
benzinga.com Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency' Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%.
benzinga.com Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
benzinga.com Trump Administration Considers Lowering US Drug Prices To International Levels: Report The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.
benzinga.com ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.
benzinga.com Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
benzinga.com Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On? Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain.
benzinga.com Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.
benzinga.com Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
benzinga.com US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget A federal judge halted NIH's plan to cap indirect grant costs at 15%, citing potential harm to research. A hearing is set for February 21.
benzinga.com Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely.
benzinga.com Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.
benzinga.com FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen' FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency.
benzinga.com Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr. Robert Kennedy Jr. revealed Trump's directive to tackle health agency corruption, promote science, and end chronic disease.
benzinga.com April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market Performance in April 2024: Utilities lead, real estate lags. S&P 500, Nasdaq 100, Dow Jones Industrial Average, small-cap and large-cap indices all decline.
benzinga.com Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.- benzinga.com Bank Of America Predicts 10 2024 Market Surprises: From Booming IPOs To Japanese Equity Surge Bank of America lists 10 market surprises; warns investors to be wary of the bond market's dovish position compared to the Fed.
- benzinga.com Pharmacy Workers Strike At CVS and Walgreens, Echoing Wider Pharma Sector Unrest In a recent surge of labor unrest, pharmacy employees from CVS Health Corporation (NYSE: CVS) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA) raised their voices by calling out sick or walking out…
benzinga.com Supreme Court Halts Purdue Pharma's $6B Settlement: Sackler Family's Shield From Opioid Lawsuits Challenged On Thursday, the Supreme Court temporarily blocked a $6-billion bankruptcy settlement by Purdue Pharma, the maker of the opioid OxyContin, that would shield the Sackler family from civil lawsuits…- benzinga.com 5 ETFs To Watch After 2022 Midterm Elections: Which Sectors Win From Republican Or Democrat Majority? The 2022 election was held on Tuesday, Nov. 8. No decision has been made as to who won many of the key battles, including several pivotal seats in the U.S. House of Representatives and U.S. Senate.
- benzinga.com Last Night's Election - A Series Of Fortunate Events For Big Pharma
- benzinga.com Getting Into The Drug Business: From NDAs To PDUFA Dates
benzinga.com Government Study: Cellphone Radiation Linked To Cancer - benzinga.com ETF Week Ahead Preview: Hoping For No November Rain
- benzinga.com These ETFs Should Love The Pfizer-Allergan News
- benzinga.com 3 Ways To Profit From Merger Activity In The Pharmaceutical Sector
benzinga.com Pharmaceutical Industry Expected To Collect Billions From Obamacare